7DHN
| The co-crystal structure of DYRK2 with a small molecule inhibitor 20 | Descriptor: | 7-methoxy-2-methylsulfanyl-9-(piperidin-4-ylmethylsulfanyl)-[1,3]thiazolo[5,4-b]quinoline, Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-16 | Release date: | 2021-11-17 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.38 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
7DHK
| The co-crystal structure of DYRK2 with a small molecule inhibitor 13 | Descriptor: | 2-methoxy-7-phenylmethoxy-9-(piperidin-4-ylmethylsulfanyl)acridine, Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-16 | Release date: | 2021-11-17 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (2.341 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
7DHV
| The co-crystal structure of DYRK2 with a small molecule inhibitor 8 | Descriptor: | 2,7-dimethoxy-9-(piperidin-4-ylmethylsulfanyl)acridine-4-carboxylic acid, Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-17 | Release date: | 2021-11-17 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.679 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
7DHO
| The co-crystal structure of DYRK2 with a small molecule inhibitor 14 | Descriptor: | 2-methoxy-9-(piperidin-4-ylmethylsulfanyl)-7-propan-2-yloxy-acridine, Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-16 | Release date: | 2021-11-17 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (3.29 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
7DJO
| The co-crystal structure of DYRK2 with a small molecule inhibitor 17 | Descriptor: | Dual specificity tyrosine-phosphorylation-regulated kinase 2, [2,7-dimethoxy-9-[[(3S)-pyrrolidin-3-yl]methylsulfanyl]acridin-4-yl]methanol | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-20 | Release date: | 2021-11-24 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.499 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
6VAC
| Mouse retromer (VPS26/VPS35/VPS29) heterotrimer | Descriptor: | Vacuolar protein sorting-associated protein 26A, Vacuolar protein sorting-associated protein 29, Vacuolar protein sorting-associated protein 35 | Authors: | Kendall, A.K, Jackson, L.P. | Deposit date: | 2019-12-17 | Release date: | 2020-02-19 | Last modified: | 2024-03-06 | Method: | ELECTRON MICROSCOPY (5.7 Å) | Cite: | Mammalian Retromer Is an Adaptable Scaffold for Cargo Sorting from Endosomes. Structure, 28, 2020
|
|
7DL6
| The co-crystal structure of DYRK2 with a small molecule inhibitor 18 | Descriptor: | Dual specificity tyrosine-phosphorylation-regulated kinase 2, [2,7-dimethoxy-9-[[(3R)-pyrrolidin-3-yl]methylsulfanyl]acridin-4-yl]methanol | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-26 | Release date: | 2021-12-01 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.648 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
6LMR
| Solution structure of cold shock domain and ssDNA complex | Descriptor: | DNA (5'-D(P*AP*AP*CP*AP*CP*CP*T)-3'), Y-box-binding protein 1 | Authors: | Fan, J, Yang, D. | Deposit date: | 2019-12-26 | Release date: | 2020-07-22 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Structural basis of DNA binding to human YB-1 cold shock domain regulated by phosphorylation. Nucleic Acids Res., 48, 2020
|
|
6VII
| |
6VPR
| |
1ELO
| ELONGATION FACTOR G WITHOUT NUCLEOTIDE | Descriptor: | ELONGATION FACTOR G | Authors: | Aevarsson, A, Brazhnikov, E, Garber, M, Zheltonosova, J, Chirgadze, Yu, Al-Karadaghi, S, Svensson, L.A, Liljas, A. | Deposit date: | 1996-03-13 | Release date: | 1996-08-01 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Three-dimensional structure of the ribosomal translocase: elongation factor G from Thermus thermophilus. EMBO J., 13, 1994
|
|
6VIK
| |
6VIH
| The ligand-free structure of mouse RABL3 | Descriptor: | Rab-like protein 3 | Authors: | Su, L, Tomchick, D.R, Beutler, B. | Deposit date: | 2020-01-13 | Release date: | 2020-04-08 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.993 Å) | Cite: | Genetic and structural studies of RABL3 reveal an essential role in lymphoid development and function. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6VIJ
| Crystal structure of mouse RABL3 in complex with GDP | Descriptor: | GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, Rab-like protein 3 | Authors: | Su, L, Tomchick, D.R, Beutler, B. | Deposit date: | 2020-01-13 | Release date: | 2020-04-08 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Genetic and structural studies of RABL3 reveal an essential role in lymphoid development and function. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6VPQ
| |
9BHJ
| |
9BHK
| MerTK in complex with small molecule inhibitor 6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide | Descriptor: | 6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide, CHLORIDE ION, Tyrosine-protein kinase Mer | Authors: | Jakob, C.G, Gurbani, D, Qiu, W. | Deposit date: | 2024-04-20 | Release date: | 2024-10-09 | Method: | X-RAY DIFFRACTION (2.106 Å) | Cite: | Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target Engagement. J.Med.Chem., 2024
|
|
6WIO
| Fab antigen complex | Descriptor: | Fab Heavy chain, Fab Light chain, Interleukin-17A | Authors: | Antonysamy, S. | Deposit date: | 2020-04-10 | Release date: | 2020-09-23 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.17 Å) | Cite: | Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. Plos One, 15, 2020
|
|
5Z5K
| Structure of the DCC-Draxin complex | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Draxin, ... | Authors: | Liu, Y, Xiao, J, Wang, J. | Deposit date: | 2018-01-18 | Release date: | 2018-06-20 | Last modified: | 2021-03-10 | Method: | X-RAY DIFFRACTION (2.493 Å) | Cite: | Structural Basis for Draxin-Modulated Axon Guidance and Fasciculation by Netrin-1 through DCC. Neuron, 97, 2018
|
|
2OUJ
| |
1CYF
| |
7DG4
| The co-crystal structure of DYRK2 with a small molecule inhibitor 6 | Descriptor: | 2,7-dimethoxy-9-(piperidin-4-ylmethylsulfanyl)acridine, Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Authors: | Wei, T, Xiao, J. | Deposit date: | 2020-11-10 | Release date: | 2021-11-10 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (2.58 Å) | Cite: | Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry. Elife, 11, 2022
|
|
2OUH
| Crystal structure of the Thrombospondin-1 N-terminal domain in complex with fractionated Heparin DP10 | Descriptor: | SULFATE ION, Thrombospondin-1 | Authors: | Tan, K, Joachimiak, A, Wang, J, Lawler, J. | Deposit date: | 2007-02-11 | Release date: | 2008-01-08 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Heparin-induced cis- and trans-Dimerization Modes of the Thrombospondin-1 N-terminal Domain. J.Biol.Chem., 283, 2008
|
|
4Q1C
| Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 8 {2,2'-[{4-[(2R)-4-{[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl}-5-propyl-2,3-dihydro-1,3-thiazol-2-yl]benzene-1,2-diyl}bis(oxy)]diethanol} | Descriptor: | 2,2'-((4-(4-(((4,6-diaminopyrimidin-2-yl)thio)methyl)-5-propylthiazol-2-yl)-1,2-phenylene)bis(oxy))bis(ethan-1-ol), Deoxycytidine kinase, URIDINE-5'-DIPHOSPHATE | Authors: | Nomme, J, Lavie, A. | Deposit date: | 2014-04-03 | Release date: | 2014-11-05 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability. J.Med.Chem., 57, 2014
|
|
4Q1F
| Human dCK C4S-S74E mutant in complex with UDP and the inhibitor 12R {N-{2-[5-(4-{(1R)-1-[(4,6-diaminopyrimidin-2-yl)sulfanyl]ethyl}-5-methyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethyl}methanesulfonamide} | Descriptor: | Deoxycytidine kinase, N-{2-[5-(4-{(1R)-1-[(4,6-diaminopyrimidin-2-yl)sulfanyl]ethyl}-5-methyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethyl}methanesulfonamide, URIDINE-5'-DIPHOSPHATE | Authors: | Nomme, J, Lavie, A. | Deposit date: | 2014-04-03 | Release date: | 2014-11-05 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability. J.Med.Chem., 57, 2014
|
|